Target General Information
Target ID T67103
Target Name Integrin alpha-V
Synonyms CD51 antigen; Vitronectin receptor alpha subunit; ITGAV
Target Type Clinical Trial
Gene Name ITGAV
Biochemical Class Integrin
UniProt ID ITAV_HUMAN
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals
Disease Rectal cancer
Example drug Abituzumab Phase 2 [532993], [1572592]
Tissue Rectal colon tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.71
Z-score: 1.79
P-value: 1.12E-02
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 0.85
Z-score: 5.80
P-value: 9.58E-09
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Multiple sclerosis
Tissue Spinal cord
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 0.25
Z-score: 1.14
P-value: 7.64E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target Gene Expression Profiles in Other Tissues of Healthy Individuals
Reference
Ref
Ref 532993Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015 Jan;26(1):132-40.
Ref 1572592NCBI GEO: archive for functional genomics data sets--update.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.